Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ZFP91_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ZFP91_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ZFP91_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ZFP91_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ZFP91_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ZFP91_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ZFP91_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ZFP91_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007053421 | Oral cavity | NEOLP | protein K63-linked ubiquitination | 16/2005 | 56/18723 | 1.80e-04 | 1.97e-03 | 16 |
GO:004586024 | Oral cavity | NEOLP | positive regulation of protein kinase activity | 63/2005 | 386/18723 | 4.41e-04 | 3.99e-03 | 63 |
GO:003367423 | Oral cavity | NEOLP | positive regulation of kinase activity | 70/2005 | 467/18723 | 2.33e-03 | 1.50e-02 | 70 |
GO:003367424 | Skin | AK | positive regulation of kinase activity | 73/1910 | 467/18723 | 1.42e-04 | 1.71e-03 | 73 |
GO:000020918 | Skin | AK | protein polyubiquitination | 41/1910 | 236/18723 | 4.78e-04 | 4.44e-03 | 41 |
GO:004586019 | Skin | AK | positive regulation of protein kinase activity | 58/1910 | 386/18723 | 1.71e-03 | 1.20e-02 | 58 |
GO:00705346 | Skin | AK | protein K63-linked ubiquitination | 13/1910 | 56/18723 | 3.55e-03 | 2.15e-02 | 13 |
GO:000020924 | Skin | cSCC | protein polyubiquitination | 103/4864 | 236/18723 | 2.57e-09 | 9.09e-08 | 103 |
GO:007053414 | Skin | cSCC | protein K63-linked ubiquitination | 29/4864 | 56/18723 | 3.25e-05 | 3.56e-04 | 29 |
GO:003367425 | Skin | cSCC | positive regulation of kinase activity | 148/4864 | 467/18723 | 3.00e-03 | 1.66e-02 | 148 |
GO:00380616 | Skin | cSCC | NIK/NF-kappaB signaling | 52/4864 | 143/18723 | 3.83e-03 | 2.05e-02 | 52 |
GO:004586025 | Skin | cSCC | positive regulation of protein kinase activity | 123/4864 | 386/18723 | 5.23e-03 | 2.64e-02 | 123 |
GO:000020920 | Thyroid | PTC | protein polyubiquitination | 128/5968 | 236/18723 | 7.81e-13 | 3.65e-11 | 128 |
GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:00705347 | Thyroid | PTC | protein K63-linked ubiquitination | 32/5968 | 56/18723 | 8.16e-05 | 6.94e-04 | 32 |
GO:00321472 | Thyroid | PTC | activation of protein kinase activity | 60/5968 | 134/18723 | 1.15e-03 | 6.71e-03 | 60 |
GO:003806113 | Thyroid | PTC | NIK/NF-kappaB signaling | 63/5968 | 143/18723 | 1.45e-03 | 8.12e-03 | 63 |
GO:0000209110 | Thyroid | ATC | protein polyubiquitination | 134/6293 | 236/18723 | 1.86e-13 | 9.20e-12 | 134 |
GO:004586026 | Thyroid | ATC | positive regulation of protein kinase activity | 185/6293 | 386/18723 | 3.00e-09 | 7.02e-08 | 185 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZFP91 | SNV | Missense_Mutation | novel | c.1024T>A | p.Tyr342Asn | p.Y342N | Q96JP5 | protein_coding | deleterious(0) | possibly_damaging(0.829) | TCGA-A1-A0SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZFP91 | SNV | Missense_Mutation | novel | c.1307G>C | p.Gly436Ala | p.G436A | Q96JP5 | protein_coding | deleterious(0.02) | benign(0.299) | TCGA-A7-A2KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
ZFP91 | SNV | Missense_Mutation | | c.1006N>T | p.His336Tyr | p.H336Y | Q96JP5 | protein_coding | deleterious(0) | possibly_damaging(0.714) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZFP91 | SNV | Missense_Mutation | | c.1562G>A | p.Ser521Asn | p.S521N | Q96JP5 | protein_coding | tolerated_low_confidence(0.11) | benign(0.038) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ZFP91 | SNV | Missense_Mutation | novel | c.1151C>T | p.Ser384Phe | p.S384F | Q96JP5 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
ZFP91 | SNV | Missense_Mutation | rs371090648 | c.449N>A | p.Arg150Gln | p.R150Q | Q96JP5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.921) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ZFP91 | SNV | Missense_Mutation | | c.1441N>A | p.Glu481Lys | p.E481K | Q96JP5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.98) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ZFP91 | SNV | Missense_Mutation | novel | c.1217N>T | p.Gly406Val | p.G406V | Q96JP5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
ZFP91 | insertion | Frame_Shift_Ins | novel | c.1314dupA | p.Phe439IlefsTer2 | p.F439Ifs*2 | Q96JP5 | protein_coding | | | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZFP91 | SNV | Missense_Mutation | | c.718N>C | p.Glu240Gln | p.E240Q | Q96JP5 | protein_coding | deleterious(0.04) | benign(0.026) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |